Literature DB >> 32110271

Adipose stromal/stem cells in regenerative medicine: Potentials and limitations.

Leandra Santos Baptista1.   

Abstract

This article presents the stem and progenitor cells from subcutaneous adipose tissue, briefly comparing them with their bone marrow counterparts, and discussing their potential for use in regenerative medicine. Subcutaneous adipose tissue differs from other mesenchymal stromal/stem cells (MSCs) sources in that it contains a pre-adipocyte population that dwells in the adventitia of robust blood vessels. Pre-adipocytes are present both in the stromal-vascular fraction (SVF; freshly isolated cells) and in the adherent fraction of adipose stromal/stem cells (ASCs; in vitro expanded cells), and have an active role on the chronic inflammation environment established in obesity, likely due their monocytic-macrophage lineage identity. The SVF and ASCs have been explored in cell therapy protocols with relative success, given their paracrine and immunomodulatory effects. Importantly, the widely explored multipotentiality of ASCs has direct application in bone, cartilage and adipose tissue engineering. The aim of this editorial is to reinforce the peculiarities of the stem and progenitor cells from subcutaneous adipose tissue, revealing the spheroids as a recently described biotechnological tool for cell therapy and tissue engineering. Innovative cell culture techniques, in particular 3D scaffold-free cultures such as spheroids, are now available to increase the potential for regeneration and differentiation of mesenchymal lineages. Spheroids are being explored not only as a model for cell differentiation, but also as powerful 3D cell culture tools to maintain the stemness and expand the regenerative and differentiation capacities of mesenchymal cell lineages. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Adipose stromal/stem cells; Cell therapy; Mesenchymal stromal/stem cells; Regenerative medicine; Spheroids; Stromal-vascular fraction; Subcutaneous adipose tissue; Tissue engineering

Year:  2020        PMID: 32110271      PMCID: PMC7031762          DOI: 10.4252/wjsc.v12.i1.1

Source DB:  PubMed          Journal:  World J Stem Cells        ISSN: 1948-0210            Impact factor:   5.326


  42 in total

Review 1.  Mesenchymal stem cells for the treatment of heart failure.

Authors:  Shunsuke Ohnishi; Hajime Ohgushi; Soichiro Kitamura; Noritoshi Nagaya
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 2.  Macrophage polarization in metabolic disorders: functions and regulation.

Authors:  Giulia Chinetti-Gbaguidi; Bart Staels
Journal:  Curr Opin Lipidol       Date:  2011-10       Impact factor: 4.776

3.  Unique multipotent cells in adult human mesenchymal cell populations.

Authors:  Yasumasa Kuroda; Masaaki Kitada; Shohei Wakao; Kouki Nishikawa; Yukihiro Tanimura; Hideki Makinoshima; Makoto Goda; Hideo Akashi; Ayumu Inutsuka; Akira Niwa; Taeko Shigemoto; Yoko Nabeshima; Tatsutoshi Nakahata; Yo-Ichi Nabeshima; Yoshinori Fujiyoshi; Mari Dezawa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

Review 4.  Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation.

Authors:  Kari Martyniak; Michal M Masternak
Journal:  Exp Gerontol       Date:  2016-12-09       Impact factor: 4.032

Review 5.  Human bone marrow mesenchymal stem cells: a systematic reappraisal via the genostem experience.

Authors:  Pierre Charbord; Erella Livne; Gerhard Gross; Thomas Häupl; Nuno M Neves; Pierre Marie; Paolo Bianco; Christian Jorgensen
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 6.  Advances in the formation, use and understanding of multi-cellular spheroids.

Authors:  Toni-Marie Achilli; Julia Meyer; Jeffrey R Morgan
Journal:  Expert Opin Biol Ther       Date:  2012-07-12       Impact factor: 4.388

7.  Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism.

Authors:  Elodie Luche; Béatrice Cousin; Lucile Garidou; Matteo Serino; Aurélie Waget; Corinne Barreau; Mireille André; Philippe Valet; Michael Courtney; Louis Casteilla; Rémy Burcelin
Journal:  Mol Metab       Date:  2013-07-04       Impact factor: 7.422

8.  Effects of metabolic inhibitors on the synthesis and release of lipoprotein lipase in cultured cells derived from the stromal-vascular fraction of rat adipose tissue.

Authors:  J M Glick; G H Rothblat
Journal:  Biochim Biophys Acta       Date:  1980-04-18

Review 9.  Bone Marrow Stromal Stem Cells in Tissue Engineering and Regenerative Medicine.

Authors:  A Polymeri; W V Giannobile; D Kaigler
Journal:  Horm Metab Res       Date:  2016-11-21       Impact factor: 2.788

Review 10.  The Synergy of Scaffold-Based and Scaffold-Free Tissue Engineering Strategies.

Authors:  Aleksandr Ovsianikov; Ali Khademhosseini; Vladimir Mironov
Journal:  Trends Biotechnol       Date:  2018-02-20       Impact factor: 21.942

View more
  3 in total

1.  Comparison of Stromal Vascular Fraction and Adipose-Derived Stem Cells for Protection of Renal Function in a Rodent Model of Ischemic Acute Kidney Injury.

Authors:  Joomin Aum; Myoung Jin Jang; Yu Seon Kim; Bo Hyun Kim; Dong Hyeon An; Jae Hyeon Han; Nayoung Suh; Choung-Soo Kim; Dalsan You
Journal:  Stem Cells Int       Date:  2022-05-06       Impact factor: 5.443

2.  Clinical applications of adipose-derived stromal vascular fraction in veterinary practice.

Authors:  Khan Sharun; Kaveri Jambagi; Rohit Kumar; Mudasir Bashir Gugjoo; Abhijit M Pawde; Hardeep Singh Tuli; Kuldeep Dhama
Journal:  Vet Q       Date:  2022-12       Impact factor: 8.071

3.  Phenotypical Characterization and Neurogenic Differentiation of Rabbit Adipose Tissue-Derived Mesenchymal Stem Cells.

Authors:  Mária Tirpáková; Jaromír Vašíček; Andrea Svoradová; Andrej Baláži; Marián Tomka; Miroslav Bauer; Alexander Makarevich; Peter Chrenek
Journal:  Genes (Basel)       Date:  2021-03-17       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.